Differential Molecular Response of Larynx Cancer Cell Lines to Combined VPA/CDDP Treatment

Overview

Journal Am J Cancer Res

Specialty Oncology

Date 2021 Jul 12

PMID 34249430

Citations 4

Authors

Ewelina Gumbarewicz

Przemko Tylzanowski

Jarogniew Luszczki

Joanna Kalafut

Arkadiusz Czerwonka

Justyna Szumilo

Anna Wawruszak

Krzysztof Kupisz

Krzysztof Polberg

Jolanta Smok-Kalwat

Andrzej Stepulak

Affiliations

Soon will be listed here.

Abstract

Successful treatment of advanced larynx squamous cell carcinoma (LSCC) remains a challenge, mainly due to limited response to chemotherapy and the phenomenon of the drug resistance. Therefore, new chemotherapeutic solutions are needed. The aim of this study was to explore benefit of combined cisplatin (CDDP) and valproic acid (VPA) therapy in patients' derived LSCC cell lines. Cell viability assay was used to establish cellular response to the drug by isobolography followed by RNA sequencing (RNAseq) analysis. were used for studies. Depending on the cell line, we found that the combinations of drugs resulted in synergistic or antagonistic pharmacological interaction, which was accompanied by significant changes in genes expression profiles. The presented therapeutic scheme efficiently blocked tumor growth in an model, corresponding to the in vitro performed studies. Interestingly the RK5 cell line, upon the combined treatment acquired a molecular profile typically associated with epithelial to mesenchymal transition (EMT). Hence, our studies demonstrates that patient-specific personalized therapy of larynx cancer should be considered and the combination of cisplatin and valproic acid should be explored as a potential therapeutic strategy in the treatment of larynx cancer.

Citing Articles

Global, regional, and national mortality of larynx cancer from 1990 to 2021: results from the global burden of disease study.

Han D, Lee H, Oung Q, Lee C World J Surg Oncol. 2025; 23(1):76.

PMID: 40055712 PMC: 11887237. DOI: 10.1186/s12957-025-03720-6.

Evaluation of the anticancer activity of RIN-1, a Notch signaling modulator, in head and neck squamous cell carcinoma.

Czerwonka A, Kalafut J, Wang S, Anameric A, Przybyszewska-Podstawka A, Mattsson J Sci Rep. 2023; 13(1):13700.

PMID: 37607974 PMC: 10444807. DOI: 10.1038/s41598-023-39472-0.

Effect of CADM1 on TPF-induced chemotherapy in laryngeal squamous cell carcinoma.

Nie J, Li L, Tan F, Wang H, Wang H, Zou L J Int Med Res. 2023; 51(4):3000605231168017.

PMID: 37114505 PMC: 10331191. DOI: 10.1177/03000605231168017.

Assessment of Pharmacological Interactions between SIRT2 Inhibitor AGK2 and Paclitaxel in Different Molecular Subtypes of Breast Cancer Cells.

Wawruszak A, Luszczki J, Czerwonka A, Okon E, Stepulak A Cells. 2022; 11(7).

PMID: 35406775 PMC: 8998062. DOI: 10.3390/cells11071211.

Vorinostat (SAHA) and Breast Cancer: An Overview.

Wawruszak A, Borkiewicz L, Okon E, Kukula-Koch W, Afshan S, Halasa M Cancers (Basel). 2021; 13(18).

PMID: 34572928 PMC: 8468501. DOI: 10.3390/cancers13184700.

References

Kim G, Chung J, Jun S, Eom D, Bae Y, Jang K . Loss of S100A14 expression is associated with the progression of adenocarcinomas of the small intestine. Pathobiology. 2012; 80(2):95-101. DOI: 10.1159/000342394. View

LITCHFIELD Jr J, WILCOXON F . A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther. 1949; 96(2):99-113. View

Katoh M, Nakagama H . FGF receptors: cancer biology and therapeutics. Med Res Rev. 2013; 34(2):280-300. DOI: 10.1002/med.21288. View

Kim D, Paggi J, Park C, Bennett C, Salzberg S . Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. Nat Biotechnol. 2019; 37(8):907-915. PMC: 7605509. DOI: 10.1038/s41587-019-0201-4. View

Bonner J, Harari P, Giralt J, Cohen R, Jones C, Sur R . Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2009; 11(1):21-8. DOI: 10.1016/S1470-2045(09)70311-0. View

Chen Y, Wang J, Chou F, Chen C, Rorke E, Chen L . Regulation of the matriptase-prostasin cell surface proteolytic cascade by hepatocyte growth factor activator inhibitor-1 during epidermal differentiation. J Biol Chem. 2010; 285(41):31755-62. PMC: 2951247. DOI: 10.1074/jbc.M110.150367. View

Dohmen A, Swartz J, van den Brekel M, Willems S, Spijker R, Neefjes J . Feasibility of Primary Tumor Culture Models and Preclinical Prediction Assays for Head and Neck Cancer: A Narrative Review. Cancers (Basel). 2015; 7(3):1716-42. PMC: 4586791. DOI: 10.3390/cancers7030858. View

Wolf G, Fisher S, Hong W, Hillman R, Spaulding M, Laramore G . Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991; 324(24):1685-90. DOI: 10.1056/NEJM199106133242402. View

Yao J, Duan L, Fan M, Yuan J, Wu X . Overexpression of BLCAP induces S phase arrest and apoptosis independent of p53 and NF-kappaB in human tongue carcinoma : BLCAP overexpression induces S phase arrest and apoptosis. Mol Cell Biochem. 2006; 297(1-2):81-92. DOI: 10.1007/s11010-006-9332-2. View

10.

Zhang P, Sun Y, Ma L . ZEB1: at the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance. Cell Cycle. 2015; 14(4):481-7. PMC: 4614883. DOI: 10.1080/15384101.2015.1006048. View

11.

Tallarida R, Porreca F, Cowan A . Statistical analysis of drug-drug and site-site interactions with isobolograms. Life Sci. 1989; 45(11):947-61. DOI: 10.1016/0024-3205(89)90148-3. View

12.

Jiang W, Zheng Y, Huang Z, Wang M, Zhang Y, Wang Z . Role of SMAD4 in the mechanism of valproic acid's inhibitory effect on prostate cancer cell invasiveness. Int Urol Nephrol. 2013; 46(5):941-6. DOI: 10.1007/s11255-013-0609-6. View

13.

Castilho R, Squarize C, Almeida L . Epigenetic Modifications and Head and Neck Cancer: Implications for Tumor Progression and Resistance to Therapy. Int J Mol Sci. 2017; 18(7). PMC: 5535996. DOI: 10.3390/ijms18071506. View

14.

Zhou S, Piao X, Wang C, Wang R, Song Z . Identification of claudin‑1, ‑3, ‑7 and ‑8 as prognostic markers in human laryngeal carcinoma. Mol Med Rep. 2019; 20(1):393-400. PMC: 6580001. DOI: 10.3892/mmr.2019.10265. View

15.

Anders S, Pyl P, Huber W . HTSeq--a Python framework to work with high-throughput sequencing data. Bioinformatics. 2014; 31(2):166-9. PMC: 4287950. DOI: 10.1093/bioinformatics/btu638. View

16.

Brunn J, Wiroth V, Kowalski M, Runge U, Sabolek M . Valproic acid in normal therapeutic concentration has no neuroprotective or differentiation influencing effects on long term expanded murine neural stem cells. Epilepsy Res. 2014; 108(4):623-33. DOI: 10.1016/j.eplepsyres.2014.02.005. View

17.

Naakka E, Tuomainen K, Wistrand H, Palkama M, Suleymanova I, Al-Samadi A . Fully Human Tumor-based Matrix in Three-dimensional Spheroid Invasion Assay. J Vis Exp. 2019; (147). DOI: 10.3791/59567. View

18.

Grabarska A, Luszczki J, Nowosadzka E, Gumbarewicz E, Jeleniewicz W, Dmoszynska-Graniczka M . Histone Deacetylase Inhibitor SAHA as Potential Targeted Therapy Agent for Larynx Cancer Cells. J Cancer. 2017; 8(1):19-28. PMC: 5264036. DOI: 10.7150/jca.16655. View

19.

Li Y, Seto E . HDACs and HDAC Inhibitors in Cancer Development and Therapy. Cold Spring Harb Perspect Med. 2016; 6(10). PMC: 5046688. DOI: 10.1101/cshperspect.a026831. View

20.

Karpathiou G, Stachowitz M, Dumollard J, Gavid M, Froudarakis M, Prades J . Gene Expression Comparison Between the Primary Tumor and its Lymph Node Metastasis in Head and Neck Squamous Cell Carcinoma: A Pilot Study. Cancer Genomics Proteomics. 2019; 16(3):155-161. PMC: 6542642. DOI: 10.21873/cgp.20121. View